Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PARP1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PARP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PARP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PARP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PARP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000616327 | Thyroid | PTC | purine nucleotide metabolic process | 170/5968 | 396/18723 | 2.02e-06 | 2.75e-05 | 170 |
GO:000914526 | Thyroid | PTC | purine nucleoside triphosphate biosynthetic process | 41/5968 | 69/18723 | 2.17e-06 | 2.91e-05 | 41 |
GO:0010833111 | Thyroid | PTC | telomere maintenance via telomere lengthening | 46/5968 | 81/18723 | 3.10e-06 | 4.04e-05 | 46 |
GO:004340124 | Thyroid | PTC | steroid hormone mediated signaling pathway | 69/5968 | 136/18723 | 3.57e-06 | 4.58e-05 | 69 |
GO:000920626 | Thyroid | PTC | purine ribonucleoside triphosphate biosynthetic process | 40/5968 | 68/18723 | 4.11e-06 | 5.11e-05 | 40 |
GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
GO:000911725 | Thyroid | PTC | nucleotide metabolic process | 202/5968 | 489/18723 | 5.46e-06 | 6.60e-05 | 202 |
GO:00346447 | Thyroid | PTC | cellular response to UV | 49/5968 | 90/18723 | 7.58e-06 | 8.77e-05 | 49 |
GO:003314310 | Thyroid | PTC | regulation of intracellular steroid hormone receptor signaling pathway | 42/5968 | 74/18723 | 8.40e-06 | 9.62e-05 | 42 |
GO:190435619 | Thyroid | PTC | regulation of telomere maintenance via telomere lengthening | 36/5968 | 61/18723 | 1.11e-05 | 1.22e-04 | 36 |
GO:00062828 | Thyroid | PTC | regulation of DNA repair | 65/5968 | 130/18723 | 1.25e-05 | 1.36e-04 | 65 |
GO:000675420 | Thyroid | PTC | ATP biosynthetic process | 34/5968 | 57/18723 | 1.41e-05 | 1.52e-04 | 34 |
GO:1901654113 | Thyroid | PTC | response to ketone | 90/5968 | 194/18723 | 1.56e-05 | 1.65e-04 | 90 |
GO:0030099113 | Thyroid | PTC | myeloid cell differentiation | 160/5968 | 381/18723 | 1.75e-05 | 1.82e-04 | 160 |
GO:000914226 | Thyroid | PTC | nucleoside triphosphate biosynthetic process | 46/5968 | 85/18723 | 1.76e-05 | 1.83e-04 | 46 |
GO:0010038112 | Thyroid | PTC | response to metal ion | 157/5968 | 373/18723 | 1.80e-05 | 1.86e-04 | 157 |
GO:005188119 | Thyroid | PTC | regulation of mitochondrial membrane potential | 41/5968 | 74/18723 | 2.36e-05 | 2.34e-04 | 41 |
GO:20010229 | Thyroid | PTC | positive regulation of response to DNA damage stimulus | 53/5968 | 105/18723 | 5.51e-05 | 4.89e-04 | 53 |
GO:000920120 | Thyroid | PTC | ribonucleoside triphosphate biosynthetic process | 40/5968 | 74/18723 | 6.30e-05 | 5.53e-04 | 40 |
GO:000915224 | Thyroid | PTC | purine ribonucleotide biosynthetic process | 78/5968 | 169/18723 | 6.88e-05 | 6.01e-04 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
PARP1 | SNV | Missense_Mutation | rs377195931 | c.919N>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PARP1 | SNV | Missense_Mutation | rs377195931 | c.919G>A | p.Asp307Asn | p.D307N | P09874 | protein_coding | tolerated(0.23) | benign(0.189) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PARP1 | SNV | Missense_Mutation | rs79529505 | c.1223N>G | p.Val408Gly | p.V408G | P09874 | protein_coding | deleterious(0) | benign(0.367) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | | c.2032N>C | p.Asp678His | p.D678H | P09874 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
PARP1 | SNV | Missense_Mutation | | c.2524G>A | p.Glu842Lys | p.E842K | P09874 | protein_coding | tolerated(0.18) | benign(0.026) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PARP1 | SNV | Missense_Mutation | novel | c.2971G>C | p.Val991Leu | p.V991L | P09874 | protein_coding | deleterious(0.01) | possibly_damaging(0.796) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | novel | c.1102A>C | p.Thr368Pro | p.T368P | P09874 | protein_coding | tolerated(0.29) | benign(0.079) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARP1 | SNV | Missense_Mutation | | c.268N>A | p.Glu90Lys | p.E90K | P09874 | protein_coding | tolerated(0.09) | possibly_damaging(0.566) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Quinazolinedione derivative 2 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 223366069 | RUCAPARIB | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | CHEMBL1094636 | NIRAPARIB | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 4-Carboxamido-isoindolinone derivative 2 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | CC-486 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | OLAPARIB | OLAPARIB | 28454547,25144364,26650448 |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | 4-Carboxamido-isoindolinone derivative 3 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Phthalazine ketone derivative 3 | | |
142 | PARP1 | ENZYME, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, DNA REPAIR, TRANSCRIPTION FACTOR COMPLEX, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | RUCAPARIB | RUCAPARIB | |